Maria Laura Avignolo
10/22/2020 10:28 AM
Clarín.com
Society
Updated 10/22/2020 10:28 AM
A day after a medical volunteer who received a placebo died in Brazil, a new study has shown that the coronavirus vaccine being developed by the University of Oxford and AstraZeneca works as planned.
A team from the University of Bristol developed a method to check that the inoculation contains all the correct parts, providing
further evidence that the vaccine works
.
Although the research has yet to be reviewed by other scientists, it was hailed as a "wonderful example of interdisciplinary collaboration" between scientists in the midst of a pandemic.
This ratification comes after confirmation that
the trials will continue
after the death of a man participating in the tests in Brazil.
This medical volunteer
had received a placebo and not the active vaccine
, according to the newspaper O Globo and the Bloomberg agency.
The new analysis method allowed British scientists to verify that the vaccine was correctly designed to
replicate the parts of the Covid-19 composition
necessary to train the immune system to fight the disease.
You will learn how to attack a protein, providing people with the biological tools necessary to fight the virus.
Dr David Matthews, from the Bristol College of Cellular and Molecular Medicine, who led the research, said: "This is an important study, as we
can confirm that the genetic instructions behind this vaccine
, which is developing as quickly and surely possible, they are followed correctly when they enter a human cell ”.
"Until now, technology has not been able to provide answers with such clarity. But now we know that the vaccine is doing everything we expected. That is good news in our fight against the disease," he continued.
Researchers at the University of Bristol were focused on showing how and when precisely the vaccine copied and used the genetic instructions programmed by its designers.
The key lies in the "spike protein" of the SARS-CoV 2 coronavirus, which produces Covid-19. Once "this spike protein" is obtained, the immune system reacts to it by training the immune system to identify the actual Covid-19 infection.
Sarah Gilbert, a professor of vaccinology at the University of Oxford and leader of the Oxford vaccine trial, added: "This is a wonderful example of interdisciplinary collaboration, using new technology to examine exactly what the vaccine does when it enters a cell. human ”.
"The study confirms that large amounts of
coronavirus
spike protein
are produced
with great precision. This largely explains the success of the vaccine in inducing a
strong immune response,
" he said.
The AstraZeneca and University of Oxford vaccine is the first in the race.
It is in advanced phase III and is the one that
the mAbxience laboratory will produce in Argentina
.
But there are another 40 vaccines in an advanced stage in different countries of the world and 170 under study, in a conjunction between scientists, laboratories and states to stop the virus.
London. Correspondent
ACE
Look also
A volunteer who was testing the Oxford vaccine in Brazil died: he would have received a placebo
UK to intentionally infect volunteers to test Covid-19 vaccines
